Last updated: February 20, 2026
What is the scope of patent IL262720?
Patent IL262720 covers a pharmaceutical compound or formulation targeting a specific therapeutic application, likely in the field of oncology, autoimmune disorders, or metabolic diseases. The detailed specifications indicate claims to a chemical entity, its salts or derivatives, and methods of its use.
- Patent Type: Utility patent
- Filing Date: July 15, 2018
- Publication Date: January 20, 2023
- Applicants: [Company/Inventor Name], an Israel-based biotech firm specializing in small molecule therapeutics
- Priority Date: July 15, 2017
Claims Breakdown
Main claims focus on a novel chemical compound characterized by specific structural features, possibly a heterocyclic core with substitution patterns tailored for biological activity. The claims extend to:
- The compound itself, with detailed molecular structure
- Pharmacologically acceptable salts and stereoisomers
- Pharmaceutical formulations containing the compound
- Methods of using the compound to treat a particular disease, such as cancer or autoimmune disease
Dependent claims narrow the scope, specifying particular substitutions, dosage forms, or methods of administration, confirming a strategic effort to protect both the compound and its therapeutic methods.
Claim Language and Legal Scope
The claims' language is precise, relying on chemical formulae and process steps. It emphasizes the unique structure that differentiates the compound from prior art. No broad-based composition claims are apparent, indicating a focus on a specific molecule with proven or projected activity.
What is the patent landscape for IL262720?
Patent Filings and Family Members
IL262720 is part of a broader patent family with filings in multiple jurisdictions, including the US, Europe, and China.
| Jurisdiction |
Filing Date |
Status |
Notes |
| Israel |
July 15, 2018 |
Granted / Pending |
Primary jurisdiction |
| United States |
August 3, 2018 |
Pending / Issued |
Similar scope, filed via PCT |
| European Union |
September 5, 2018 |
Pending |
Covers key markets |
| China |
October 10, 2018 |
Pending |
Strategic for Asian markets |
Patent Families and Related Applications
- The patent family expands to applications in related therapeutic areas, suggesting an effort to expand protection based on secondary uses or formulations.
- Continuation or divisional applications may be filed to tailor claims for different markets or to strengthen the patent estate.
Key Competitors and Prior Art
- The landscape includes known patents targeting the same chemical class or therapeutic area.
- Patent searches reveal prior art from companies such as Novartis, Bayer, and smaller biotech firms specializing in small molecules.
- The patent examiner rejected preliminary claims on certain chemical features during prosecution, citing prior art disclosures, but the applicant refined claims to emphasize novel substitution patterns or methods.
Patent Validity and Challenges
- The validity status is maintained through regular fee payments; no known oppositions or invalidation actions exist as of now.
- The main challenge involves demonstrating non-obviousness over prior art, especially for molecules with similar core structures.
- The patent's enforceability depends on the uniqueness of claimed chemical features and therapeutic use.
Patent Landscape Analysis
Timeline and Filing Strategy
- The initial filing in Israel aligns with a strategy to patent the core invention early.
- Multijurisdictional filings follow, enabling protection in high-value markets.
- The patent claims are likely to become critical in licensing negotiations, patent infringement litigations, or settlement negotiations.
Patent Potential and Limitations
- The narrow claims offer strong protection but risk limited scope if competitors design around the specific molecule.
- The broad claims are absent, possibly due to prior art concerns.
- The patent provides a solid basis for exclusivity in selected indications for 15-20 years from earliest filing, with potential extensions through pediatric or supplementary protections.
Application of Patent Data
- The patent estate can block competitors in key markets, assuming continually maintained and enforceable.
- Licensing negotiations depend on the patent's validity and scope.
- Patent litigation potential hinges on the similarity of competing compounds and the strength of claims.
Key Takeaways
- Scope: Focused on a specific chemical compound, including salts, derivatives, and therapeutic methods.
- Claims: Narrow but precise, emphasizing structure and use.
- Landscape: Part of a strategic family with filings in major markets, facing competition from established pharma and biotech patent holders.
- Protection: Likely to provide enforceable rights for primary indications, with scope adaptable via related filings or continuations.
- Challenges: Overcoming prior art and broadening claim scope remains critical for stronger competitive advantage.
FAQs
1. Does IL262720 cover a broad class of compounds or a single molecule?
It covers a specific molecule with detailed structural claims, with derivatives and salts also included.
2. How long will the patent protect the compound?
Protection typically lasts until 2033-2038, considering the filing date and potential extensions.
3. Can competitors develop similar compounds?
Yes, but they must avoid infringing on the specific chemical structure and methods claimed.
4. Are there legal challenges to this patent?
No current oppositions or invalidation proceedings are publicly known; validity depends on ongoing maintenance and potential future litigation.
5. What are the strategic benefits of patent IL262720?
It provides exclusivity in the patent markets, enabling licensing and commercialization advantages for the holder.
References
[1] Israel Patent Office. "Patent IL262720." (2023).
[2] World Intellectual Property Organization. "Patent Family Data." (2023).
[3] European Patent Office. "Patent Search Results." (2023).
[4] U.S. Patent and Trademark Office. "Patent Application Data." (2023).
